Randomized Trialhigh evidence
Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial.
GeroScience·July 30, 2026·PMID 42530810
Why it mattersDeclining NAD+ is implicated in aging and metabolic dysfunction, but oral NAD+ precursors face bioavailability hurdles. This study demonstrates that a physicochemically modified oral NAD+ formulation can selectively boost intracellular NAD without raising plasma levels, offering a potential strategy for targeted NAD repletion in longevity and metabolic health.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled